FDA granted accelerated approval for two combinations of venetoclax on November 2018, for newly diagnosed AML patients ineligible to receive intensive induction, or aged 75 or older: First, Venclexta with azacitidine or decitabine and second, being Venclexta in combination with LDAC. Learn more as our DRG Analyst Jorrit Schäfer presents the current market scenario of venetoclax in combination with hypomethylating agent and LDAC respectively in United States.


Biotech set for good start to 2021

View Now